Who
John P. Schmid
Director
Company insider
Files Form 4 as: Director, BlossomHill Therapeutics; Director, AnaptysBio; Director, First Tracks Biotherapeutics; Director, Design Therapeutics; Other, BridgeBio Oncology Therapeutics; Director, Poseida Therapeutics; Director, Xeris Biopharma Holdings; Director, Xeris Pharmaceuticals.
In numbers
- Trades disclosed
- 216
- Buys
- 8
- Sells
- 21
- Bought
- $342K
- Sold
- $2.4M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 3 Nov 2010
- Last trade
- 10 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Bought | $96K6,000 at $16.00 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Bought | $96K6,000 at $16.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ANAB AnaptysBioBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
News
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung CancerBLSM · manilatimes.net · 22 Oct 2026Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)ANAB · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name John P. Schmid; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.